Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Payables (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Payables data on record, last reported at $12.5 million in Q4 2025.

  • For Q4 2025, Payables fell 11.9% year-over-year to $12.5 million; the TTM value through Dec 2025 reached $12.5 million, down 11.9%, while the annual FY2025 figure was $12.5 million, 11.9% down from the prior year.
  • Payables reached $12.5 million in Q4 2025 per ARQT's latest filing, up from $5.8 million in the prior quarter.
  • Across five years, Payables topped out at $24.5 million in Q1 2025 and bottomed at $4.9 million in Q3 2021.
  • Average Payables over 5 years is $12.1 million, with a median of $12.5 million recorded in 2022.
  • Peak YoY movement for Payables: soared 103.34% in 2023, then tumbled 70.01% in 2025.
  • A 5-year view of Payables shows it stood at $7.4 million in 2021, then rose by 20.05% to $8.8 million in 2022, then soared by 35.86% to $12.0 million in 2023, then grew by 18.58% to $14.2 million in 2024, then dropped by 11.9% to $12.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $12.5 million in Q4 2025, $5.8 million in Q3 2025, and $15.1 million in Q2 2025.